This is a summary for the hepatitis B community providing straightforward information on the results of a study called ‘B-Clear’. Hepatitis B is an infection of the liver caused by a virus. Chronic hepatitis B is a long-lasting infection and occurs when the body is unable to fight off the virus and it persists in the blood and liver. Chronic hepatitis B virus infection is a major global health problem affecting approximately 296 million people. Current standard therapies, such as nucleotide analogs (antiviral therapy), rarely lead to a cure. This study investigated a new treatment for chronic hepatitis B virus infection, called bepirovirsen, alone or in combination with nucleotide analogs (antiviral therapy), in participants with chronic hepatitis B virus infection. The duration of treatment was 6 months.This Plain Language Summary of Publication article from Future Virology summarises the results of a study called B-Clear. Hepatitis B is a viral infection of the liver and chronic hepatitis B is a long-lasting infection where the infection stays in the blood and liver. The B-Clear study investigated a new treatment for chronic hepatitis B infection called bepirovirsen, alone, or in combination with antiviral therapies ( such as nucleotide analogs).

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine using the link to read the original article.